CONTINUE TO SITE
OR WAIT 15 SECS
Alumis Inc., a US-based clinical-stage biopharmaceutical company and Japan's Kaken Pharmaceutical Co. have ent
Merck, known as MSD outside of the United States and Canada, and Jiangsu Hengrui Pharmaceuticals Co., a global
China based The United Laboratories International Holdings Limited (TUL) and Danish pharmaceutical company Nov
Diabetic wounds often lead to severe complications that can result in amputations. These chronic and non-heali
University of Queensland researchers are designing nanotechnology they believe could improve how we treat the
A new ‘nanoball’ vaccine platform developed by experts in Japan will be tested as part of new rese
The Ministry of Health in Egypt has signed a Memorandum of Understanding (MoU) with Siemens Healthineers on to
ABL Diagnostics, a Euronext-listed leader in molecular diagnostics, has announced an exclusive distribution ag
Novotech, a global leading full-service clinical Contract Research Organization (CRO), and Acrostar, a provide
Avance Clinical, a leading full-service global Contract Research Organization (CRO) specialising in high-quali
Mitigating PATENT CLIFF Fallout
Monoclonal antibodies (mAbs) represent a $279.8 billion market, projected to reach $804 billion by 2033, according to a report from Dimension Market Research. With patents for many of these valuable drugs set to expire in the coming years, the industry faces significant challenges. In this story, we examine 11 blockbuster mAbs whose patents will expire between 2025 and 2030. These expirations, affecting some of pharma's biggest players, will have a major impact on the market and their revenue streams.
ISPOR 2025
ISPOR
info@ispor.org https://www.ispor.org/conferences-education/event/2025/05/13/default-calendar/ispor-2025Montreal
Novel ConjugatesSummit 2025
Hanson Wade
info@hansonwade.com https://novel-conjugates.com/hanson-wade/Boston
